Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,363 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07023848Enrolling by invitationEarly Phase 1
Imaging study for HER2-positive cancers using a special tracer
This study uses a radioactive tracer to take pictures of tumors that have a protein called HER2. It may help doctors see where the cancer is in your body and could guide future treatment decisions.
Wuxi, JiangsuAges 18–75 - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT07030569Recruiting
Predicting treatment response in metastatic breast cancer
This trial studies how well CT and PET scans can predict if a certain type of breast cancer will respond to a targeted treatment. It focuses on women who had a biopsy of the liver, lung, or chest lining after the cancer spread.
MilanAges Any age - NCT04850729Recruiting
Study links surgery medicines to the stomach tumor environment
This trial looks at how medicines given around the time of stomach cancer surgery may change the “tumor microenvironment,” which is the biology around the tumor. It may help doctors better understand which perioperative treatments work best for locally advanced, operable stomach cancer.
Guangzhou, GuangdongAges 18–75 - NCT05357768Recruiting
Research study of rare round cell sarcoma biology and outcomes
This study collects information and archived tumor samples from people with undifferentiated round cell sarcoma to better understand the disease. It may help future diagnoses and treatments by linking lab findings in tumor tissue to clinical outcomes.
Bologna, BOAges Any age - NCT07020117RecruitingPhase 1
Study of AKY-1189 for advanced solid tumors
This trial tests a new radioactive drug, AKY-1189, for people with solid tumors that have spread or cannot be removed. It may help if other treatments have stopped working.
Duarte, CaliforniaAges 18 years+ - NCT07022002RecruitingPhase 2
Testing a new drug for HER2-positive advanced cancers
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07023289RecruitingPhase 2
Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Huntsville, AlabamaAges 18 years+ - NCT07021846Recruiting
Higher-dose radiation for early breast cancer in young women
This study tests a higher-dose, faster radiation treatment for young women with early breast cancer who have certain risk factors. The goal is to reduce the chance of cancer coming back while keeping side effects low.
RomaAges 18–50 - NCT07023640Recruiting
Imaging test for tumors using a new tracer agent
This trial tests a new imaging method (68Ga-DOTA-mPNE PET/CT) to see if it can help detect cancers. It's for people who haven't had chemotherapy or radiation yet and will have a biopsy or surgery.
Beijing, Beijing MunicipalityAges 18–70 - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT07018622RecruitingPhase 2
Protecting kidneys from platinum chemotherapy damage
This trial tests a way to protect your kidneys while you receive platinum-based chemotherapy (cisplatin or carboplatin) for a solid tumor. It may help reduce the risk of kidney damage so you can complete your treatment more safely.
México, TlalpanAges 18 years+ - NCT07020780Recruiting
Short-course radiation for high-risk breast cancer
This trial tests a short, more intense radiation schedule for women with certain breast cancer types or who are under 40. It aims to reduce treatment time while still targeting the whole breast and any high-risk areas.
MilanAges 18–70 - NCT07006727RecruitingPhase 1
Study of a new drug for advanced DLL3-positive solid tumors
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
Iowa City, IowaAges 18–100 - NCT07003321RecruitingPhase 2
Testing HRS-4508 for advanced non-small cell lung cancer
This trial tests an experimental drug called HRS-4508 for people with advanced non-small cell lung cancer that has stopped responding to standard treatments or cannot tolerate them. The goal is to see if it can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07003542RecruitingPhase 2
Sitagliptin for people with high-grade brain tumors
This trial tests whether sitagliptin, a medicine usually used for diabetes, can help people with a fast-growing type of brain tumor (grade 4 glioma). You will take sitagliptin before your planned surgery, and researchers will study how it affects your tumor.
Cleveland, OhioAges 18 years+ - NCT07009184RecruitingEarly Phase 1
Imaging study for HER2-positive cancers using TGW211
This trial tests whether a new imaging agent called TGW211 can help doctors see HER2-positive cancers more clearly on scans. It may lead to better ways to track these cancers in the future.
Nijmegen, GelderlandAges 18 years+ - NCT07004244RecruitingPhase 1
KRAS vaccine study for people with KRAS-mutated cancers
This trial tests a vaccine designed to target cancers with KRAS mutations. It may be an option if your cancer has a KRAS mutation and you have either tried other treatments without success or have a newly diagnosed, early-stage lung adenocarcinoma.
Chengdu, SichuanAges 18 years+ - NCT07004582Recruiting
Lab study using mini-tumors to test prostate cancer treatments
This trial uses leftover tumor tissue from biopsies or brachytherapy to grow mini-tumors in the lab. Researchers want to test different treatments on these mini-tumors to find the best options for patients with high-risk or recurrent prostate cancer.
Heerlen, LimburgAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06994806RecruitingPhase 1
KQB168 for advanced solid tumors post immunotherapy
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
Phoenix, ArizonaAges 18 years+ - NCT07001085Recruiting
Blood test to monitor liver cancer after surgery
This study uses a simple blood test to monitor tiny pieces of tumor DNA (ctDNA) in people with colorectal cancer that spread to the liver or with liver cancer (HCC), before and after liver surgery or transplant. It aims to help doctors detect cancer return earlier and guide treatment.
Warsaw, Masovian VoivodeshipAges 18–75 - NCT07003022RecruitingPhase 2
Two-drug combo for advanced colorectal cancer
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Shanghai, ChinaAges 18–80 - NCT06996249Recruiting
Thoracic cancer data collection study
This study collects medical information from people with suspected or confirmed thoracic cancer. The goal is to learn more about these cancers and improve future care.
Ede, GelderlandAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,363 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.